Effect	O
of	O
race	B:C0034510
and	O
ethnicity	O
on	O
vildagliptin	O
efficacy	O
:	O
A	O
pooled	O
analysis	O
of	O
phase	O
II	I:C0282460
and	O
III	O
studies	I:C0282461

Effect	O
of	O
race	O
and	O
ethnicity	B:C0015031
on	O
vildagliptin	O
efficacy	O
:	O
A	O
pooled	O
analysis	O
of	O
phase	O
II	I:C0282460
and	O
III	O
studies	I:C0282461

Effect	O
of	O
race	O
and	O
ethnicity	O
on	O
vildagliptin	B:C1570906
efficacy	O
:	O
A	O
pooled	O
analysis	O
of	O
phase	O
II	I:C0282460
and	O
III	O
studies	I:C0282461

Effect	O
of	O
race	O
and	O
ethnicity	O
on	O
vildagliptin	O
efficacy	O
:	O
A	O
pooled	O
analysis	O
of	O
phase	B:C0282460
II	I:C0282460
and	O
III	O
studies	I:C0282461

Effect	O
of	O
race	O
and	O
ethnicity	O
on	O
vildagliptin	O
efficacy	O
:	O
A	O
pooled	O
analysis	O
of	O
phase	O
II	I:C0282460
and	O
III	B:C0282461
studies	I:C0282461

To	O
determine	O
the	O
impact	O
of	O
race	B:C0034510
and	O
ethnicity	O
on	O
the	O
efficacy	O
,	O
body	O
weight	O
and	O
hypoglycaemia	O
incidence	O
with	O
vildagliptin	O
treatment	O
in	O
patients	O
with	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
using	O
patient	O
-	I:C1516606
level	I:C1516606
data	I:C1516606
from	O
the	O
vildagliptin	O
clinical	O
trial	I:C0008976
programme	I:C0008976
.	O

To	O
determine	O
the	O
impact	O
of	O
race	O
and	O
ethnicity	B:C0015031
on	O
the	O
efficacy	O
,	O
body	O
weight	O
and	O
hypoglycaemia	O
incidence	O
with	O
vildagliptin	O
treatment	O
in	O
patients	O
with	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
using	O
patient	O
-	I:C1516606
level	I:C1516606
data	I:C1516606
from	O
the	O
vildagliptin	O
clinical	O
trial	I:C0008976
programme	I:C0008976
.	O

To	O
determine	O
the	O
impact	O
of	O
race	O
and	O
ethnicity	O
on	O
the	O
efficacy	O
,	O
body	O
weight	O
and	O
hypoglycaemia	B:C0020615
incidence	O
with	O
vildagliptin	O
treatment	O
in	O
patients	O
with	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
using	O
patient	O
-	I:C1516606
level	I:C1516606
data	I:C1516606
from	O
the	O
vildagliptin	O
clinical	O
trial	I:C0008976
programme	I:C0008976
.	O

To	O
determine	O
the	O
impact	O
of	O
race	O
and	O
ethnicity	O
on	O
the	O
efficacy	O
,	O
body	O
weight	O
and	O
hypoglycaemia	O
incidence	O
with	O
vildagliptin	B:C1570906
treatment	O
in	O
patients	O
with	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
using	O
patient	O
-	I:C1516606
level	I:C1516606
data	I:C1516606
from	O
the	O
vildagliptin	O
clinical	O
trial	I:C0008976
programme	I:C0008976
.	O

To	O
determine	O
the	O
impact	O
of	O
race	O
and	O
ethnicity	O
on	O
the	O
efficacy	O
,	O
body	O
weight	O
and	O
hypoglycaemia	O
incidence	O
with	O
vildagliptin	O
treatment	B:C0087111
in	O
patients	O
with	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
using	O
patient	O
-	I:C1516606
level	I:C1516606
data	I:C1516606
from	O
the	O
vildagliptin	O
clinical	O
trial	I:C0008976
programme	I:C0008976
.	O

To	O
determine	O
the	O
impact	O
of	O
race	O
and	O
ethnicity	O
on	O
the	O
efficacy	O
,	O
body	O
weight	O
and	O
hypoglycaemia	O
incidence	O
with	O
vildagliptin	O
treatment	O
in	O
patients	O
with	O
type	B:C0011860
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
using	O
patient	O
-	I:C1516606
level	I:C1516606
data	I:C1516606
from	O
the	O
vildagliptin	O
clinical	O
trial	I:C0008976
programme	I:C0008976
.	O

To	O
determine	O
the	O
impact	O
of	O
race	O
and	O
ethnicity	O
on	O
the	O
efficacy	O
,	O
body	O
weight	O
and	O
hypoglycaemia	O
incidence	O
with	O
vildagliptin	O
treatment	O
in	O
patients	O
with	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
using	O
patient	B:C1516606
-	I:C1516606
level	I:C1516606
data	I:C1516606
from	O
the	O
vildagliptin	O
clinical	O
trial	I:C0008976
programme	I:C0008976
.	O

To	O
determine	O
the	O
impact	O
of	O
race	O
and	O
ethnicity	O
on	O
the	O
efficacy	O
,	O
body	O
weight	O
and	O
hypoglycaemia	O
incidence	O
with	O
vildagliptin	O
treatment	O
in	O
patients	O
with	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
using	O
patient	O
-	I:C1516606
level	I:C1516606
data	I:C1516606
from	O
the	O
vildagliptin	B:C1570906
clinical	O
trial	I:C0008976
programme	I:C0008976
.	O

To	O
determine	O
the	O
impact	O
of	O
race	O
and	O
ethnicity	O
on	O
the	O
efficacy	O
,	O
body	O
weight	O
and	O
hypoglycaemia	O
incidence	O
with	O
vildagliptin	O
treatment	O
in	O
patients	O
with	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
using	O
patient	O
-	I:C1516606
level	I:C1516606
data	I:C1516606
from	O
the	O
vildagliptin	O
clinical	B:C0008976
trial	I:C0008976
programme	I:C0008976
.	O

Data	O
from	O
22	O
randomized	O
,	O
placebo	B:C1706408
-	I:C1706408
controlled	I:C1706408
global	O
and	O
local	O
(	O
Japan	O
,	O
China	O
)	O
registration	O
studies	I:C0008972
of	O
vildagliptin	O
(	O
50	O
mg	O
once	O
-	O
daily	O
or	O
twice	O
-	O
daily	O
)	O
of	O
≥	O
12	O
-	O
week	O
duration	O
were	O
analysed	O
by	O
race	O
(	O
Caucasian	O
[	O
n	O
=	O
2764	O
]	O
and	O
Asian	O
[	O
n	O
=	O
2232	O
]	O
)	O
and	O
by	O
ethnicity	O
(	O
Japanese	O
,	O
Chinese	O
,	O
and	O
Indian	O
)	O
.	O

Data	O
from	O
22	O
randomized	O
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
global	O
and	O
local	B:C0205276
(	O
Japan	O
,	O
China	O
)	O
registration	O
studies	I:C0008972
of	O
vildagliptin	O
(	O
50	O
mg	O
once	O
-	O
daily	O
or	O
twice	O
-	O
daily	O
)	O
of	O
≥	O
12	O
-	O
week	O
duration	O
were	O
analysed	O
by	O
race	O
(	O
Caucasian	O
[	O
n	O
=	O
2764	O
]	O
and	O
Asian	O
[	O
n	O
=	O
2232	O
]	O
)	O
and	O
by	O
ethnicity	O
(	O
Japanese	O
,	O
Chinese	O
,	O
and	O
Indian	O
)	O
.	O

Data	O
from	O
22	O
randomized	O
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
global	O
and	O
local	O
(	O
Japan	B:C0022341
,	O
China	O
)	O
registration	O
studies	I:C0008972
of	O
vildagliptin	O
(	O
50	O
mg	O
once	O
-	O
daily	O
or	O
twice	O
-	O
daily	O
)	O
of	O
≥	O
12	O
-	O
week	O
duration	O
were	O
analysed	O
by	O
race	O
(	O
Caucasian	O
[	O
n	O
=	O
2764	O
]	O
and	O
Asian	O
[	O
n	O
=	O
2232	O
]	O
)	O
and	O
by	O
ethnicity	O
(	O
Japanese	O
,	O
Chinese	O
,	O
and	O
Indian	O
)	O
.	O

Data	O
from	O
22	O
randomized	O
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
global	O
and	O
local	O
(	O
Japan	O
,	O
China	B:C0008115
)	O
registration	O
studies	I:C0008972
of	O
vildagliptin	O
(	O
50	O
mg	O
once	O
-	O
daily	O
or	O
twice	O
-	O
daily	O
)	O
of	O
≥	O
12	O
-	O
week	O
duration	O
were	O
analysed	O
by	O
race	O
(	O
Caucasian	O
[	O
n	O
=	O
2764	O
]	O
and	O
Asian	O
[	O
n	O
=	O
2232	O
]	O
)	O
and	O
by	O
ethnicity	O
(	O
Japanese	O
,	O
Chinese	O
,	O
and	O
Indian	O
)	O
.	O

Data	O
from	O
22	O
randomized	O
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
global	O
and	O
local	O
(	O
Japan	O
,	O
China	O
)	O
registration	B:C0008972
studies	I:C0008972
of	O
vildagliptin	O
(	O
50	O
mg	O
once	O
-	O
daily	O
or	O
twice	O
-	O
daily	O
)	O
of	O
≥	O
12	O
-	O
week	O
duration	O
were	O
analysed	O
by	O
race	O
(	O
Caucasian	O
[	O
n	O
=	O
2764	O
]	O
and	O
Asian	O
[	O
n	O
=	O
2232	O
]	O
)	O
and	O
by	O
ethnicity	O
(	O
Japanese	O
,	O
Chinese	O
,	O
and	O
Indian	O
)	O
.	O

Data	O
from	O
22	O
randomized	O
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
global	O
and	O
local	O
(	O
Japan	O
,	O
China	O
)	O
registration	O
studies	I:C0008972
of	O
vildagliptin	B:C1570906
(	O
50	O
mg	O
once	O
-	O
daily	O
or	O
twice	O
-	O
daily	O
)	O
of	O
≥	O
12	O
-	O
week	O
duration	O
were	O
analysed	O
by	O
race	O
(	O
Caucasian	O
[	O
n	O
=	O
2764	O
]	O
and	O
Asian	O
[	O
n	O
=	O
2232	O
]	O
)	O
and	O
by	O
ethnicity	O
(	O
Japanese	O
,	O
Chinese	O
,	O
and	O
Indian	O
)	O
.	O

Data	O
from	O
22	O
randomized	O
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
global	O
and	O
local	O
(	O
Japan	O
,	O
China	O
)	O
registration	O
studies	I:C0008972
of	O
vildagliptin	O
(	O
50	O
mg	O
once	O
-	O
daily	O
or	O
twice	O
-	O
daily	O
)	O
of	O
≥	O
12	O
-	O
week	O
duration	O
were	O
analysed	O
by	O
race	B:C0034510
(	O
Caucasian	O
[	O
n	O
=	O
2764	O
]	O
and	O
Asian	O
[	O
n	O
=	O
2232	O
]	O
)	O
and	O
by	O
ethnicity	O
(	O
Japanese	O
,	O
Chinese	O
,	O
and	O
Indian	O
)	O
.	O

Data	O
from	O
22	O
randomized	O
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
global	O
and	O
local	O
(	O
Japan	O
,	O
China	O
)	O
registration	O
studies	I:C0008972
of	O
vildagliptin	O
(	O
50	O
mg	O
once	O
-	O
daily	O
or	O
twice	O
-	O
daily	O
)	O
of	O
≥	O
12	O
-	O
week	O
duration	O
were	O
analysed	O
by	O
race	O
(	O
Caucasian	B:C0043157
[	O
n	O
=	O
2764	O
]	O
and	O
Asian	O
[	O
n	O
=	O
2232	O
]	O
)	O
and	O
by	O
ethnicity	O
(	O
Japanese	O
,	O
Chinese	O
,	O
and	O
Indian	O
)	O
.	O

Data	O
from	O
22	O
randomized	O
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
global	O
and	O
local	O
(	O
Japan	O
,	O
China	O
)	O
registration	O
studies	I:C0008972
of	O
vildagliptin	O
(	O
50	O
mg	O
once	O
-	O
daily	O
or	O
twice	O
-	O
daily	O
)	O
of	O
≥	O
12	O
-	O
week	O
duration	O
were	O
analysed	O
by	O
race	O
(	O
Caucasian	O
[	O
n	O
=	O
2764	O
]	O
and	O
Asian	B:C0078988
[	O
n	O
=	O
2232	O
]	O
)	O
and	O
by	O
ethnicity	O
(	O
Japanese	O
,	O
Chinese	O
,	O
and	O
Indian	O
)	O
.	O

Data	O
from	O
22	O
randomized	O
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
global	O
and	O
local	O
(	O
Japan	O
,	O
China	O
)	O
registration	O
studies	I:C0008972
of	O
vildagliptin	O
(	O
50	O
mg	O
once	O
-	O
daily	O
or	O
twice	O
-	O
daily	O
)	O
of	O
≥	O
12	O
-	O
week	O
duration	O
were	O
analysed	O
by	O
race	O
(	O
Caucasian	O
[	O
n	O
=	O
2764	O
]	O
and	O
Asian	O
[	O
n	O
=	O
2232	O
]	O
)	O
and	O
by	O
ethnicity	B:C0015031
(	O
Japanese	O
,	O
Chinese	O
,	O
and	O
Indian	O
)	O
.	O

Data	O
from	O
22	O
randomized	O
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
global	O
and	O
local	O
(	O
Japan	O
,	O
China	O
)	O
registration	O
studies	I:C0008972
of	O
vildagliptin	O
(	O
50	O
mg	O
once	O
-	O
daily	O
or	O
twice	O
-	O
daily	O
)	O
of	O
≥	O
12	O
-	O
week	O
duration	O
were	O
analysed	O
by	O
race	O
(	O
Caucasian	O
[	O
n	O
=	O
2764	O
]	O
and	O
Asian	O
[	O
n	O
=	O
2232	O
]	O
)	O
and	O
by	O
ethnicity	O
(	O
Japanese	B:C1556094
,	O
Chinese	O
,	O
and	O
Indian	O
)	O
.	O

Data	O
from	O
22	O
randomized	O
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
global	O
and	O
local	O
(	O
Japan	O
,	O
China	O
)	O
registration	O
studies	I:C0008972
of	O
vildagliptin	O
(	O
50	O
mg	O
once	O
-	O
daily	O
or	O
twice	O
-	O
daily	O
)	O
of	O
≥	O
12	O
-	O
week	O
duration	O
were	O
analysed	O
by	O
race	O
(	O
Caucasian	O
[	O
n	O
=	O
2764	O
]	O
and	O
Asian	O
[	O
n	O
=	O
2232	O
]	O
)	O
and	O
by	O
ethnicity	O
(	O
Japanese	O
,	O
Chinese	B:C0152035
,	O
and	O
Indian	O
)	O
.	O

Data	O
from	O
22	O
randomized	O
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
global	O
and	O
local	O
(	O
Japan	O
,	O
China	O
)	O
registration	O
studies	I:C0008972
of	O
vildagliptin	O
(	O
50	O
mg	O
once	O
-	O
daily	O
or	O
twice	O
-	O
daily	O
)	O
of	O
≥	O
12	O
-	O
week	O
duration	O
were	O
analysed	O
by	O
race	O
(	O
Caucasian	O
[	O
n	O
=	O
2764	O
]	O
and	O
Asian	O
[	O
n	O
=	O
2232	O
]	O
)	O
and	O
by	O
ethnicity	O
(	O
Japanese	O
,	O
Chinese	O
,	O
and	O
Indian	B:C1524069
)	O
.	O

The	O
placebo	O
-	O
subtracted	O
differences	O
in	O
the	O
change	O
in	O
glycated	B:C0017853
haemoglobin	I:C0017853
(	O
HbA1c	O
)	O
and	O
body	O
weight	O
from	O
baseline	O
to	O
week	O
12	O
or	O
week	O
24	O
were	O
evaluated	O
by	O
race	O
or	O
ethnicity	O
using	O
repeated	O
measure	O
analysis	O
of	O
unstructured	O
covariance	O
.	O

The	O
placebo	O
-	O
subtracted	O
differences	O
in	O
the	O
change	O
in	O
glycated	O
haemoglobin	I:C0017853
(	O
HbA1c	B:C0017853
)	O
and	O
body	O
weight	O
from	O
baseline	O
to	O
week	O
12	O
or	O
week	O
24	O
were	O
evaluated	O
by	O
race	O
or	O
ethnicity	O
using	O
repeated	O
measure	O
analysis	O
of	O
unstructured	O
covariance	O
.	O

The	O
placebo	O
-	O
subtracted	O
differences	O
in	O
the	O
change	O
in	O
glycated	O
haemoglobin	I:C0017853
(	O
HbA1c	O
)	O
and	O
body	O
weight	O
from	O
baseline	O
to	O
week	O
12	O
or	O
week	O
24	O
were	O
evaluated	O
by	O
race	B:C0034510
or	O
ethnicity	O
using	O
repeated	O
measure	O
analysis	O
of	O
unstructured	O
covariance	O
.	O

The	O
placebo	O
-	O
subtracted	O
differences	O
in	O
the	O
change	O
in	O
glycated	O
haemoglobin	I:C0017853
(	O
HbA1c	O
)	O
and	O
body	O
weight	O
from	O
baseline	O
to	O
week	O
12	O
or	O
week	O
24	O
were	O
evaluated	O
by	O
race	O
or	O
ethnicity	B:C0015031
using	O
repeated	O
measure	O
analysis	O
of	O
unstructured	O
covariance	O
.	O

Hypoglycaemia	B:C0020615
incidences	O
were	O
summarized	O
using	O
descriptive	O
statistics	O
.	O

The	O
HbA1c	B:C0017853
reduction	O
from	O
baseline	O
with	O
vildagliptin	O
was	O
similar	O
across	O
the	O
racial	O
/	O
ethnic	O
subgroups	I:C0015031
(	O
-	O
0.83	O
%	O
±	O
0.02	O
%	O
to	O
-	O
1.01	O
%	O
±	O
0.05	O
%	O
)	O
.	O

The	O
HbA1c	O
reduction	B:C0441610
from	O
baseline	O
with	O
vildagliptin	O
was	O
similar	O
across	O
the	O
racial	O
/	O
ethnic	O
subgroups	I:C0015031
(	O
-	O
0.83	O
%	O
±	O
0.02	O
%	O
to	O
-	O
1.01	O
%	O
±	O
0.05	O
%	O
)	O
.	O

The	O
HbA1c	O
reduction	O
from	O
baseline	O
with	O
vildagliptin	B:C1570906
was	O
similar	O
across	O
the	O
racial	O
/	O
ethnic	O
subgroups	I:C0015031
(	O
-	O
0.83	O
%	O
±	O
0.02	O
%	O
to	O
-	O
1.01	O
%	O
±	O
0.05	O
%	O
)	O
.	O

The	O
HbA1c	O
reduction	O
from	O
baseline	O
with	O
vildagliptin	O
was	O
similar	O
across	O
the	O
racial	B:C0034510
/	O
ethnic	O
subgroups	I:C0015031
(	O
-	O
0.83	O
%	O
±	O
0.02	O
%	O
to	O
-	O
1.01	O
%	O
±	O
0.05	O
%	O
)	O
.	O

The	O
HbA1c	O
reduction	O
from	O
baseline	O
with	O
vildagliptin	O
was	O
similar	O
across	O
the	O
racial	O
/	O
ethnic	B:C0015031
subgroups	I:C0015031
(	O
-	O
0.83	O
%	O
±	O
0.02	O
%	O
to	O
-	O
1.01	O
%	O
±	O
0.05	O
%	O
)	O
.	O

Placebo	O
-	O
corrected	O
HbA1c	B:C0017853
reduction	O
was	O
similar	O
between	O
Caucasian	O
(	O
-	O
0.68	O
%	O
±	O
0.03	O
%	O
)	O
and	O
Asian	O
(	O
-	O
0.80	O
%	O
±	O
0.03	O
%	O
)	O
patients	O
(	O
P	O
value	O
for	O
interaction	O
=	O
.56	O
)	O
;	O
analysis	O
by	O
race	O
and	O
ethnicity	O
showed	O
better	O
efficacy	O
(	O
P	O
<	O
.02	O
)	O
in	O
Japanese	O
patients	O
.	O

Placebo	O
-	O
corrected	O
HbA1c	O
reduction	B:C0441610
was	O
similar	O
between	O
Caucasian	O
(	O
-	O
0.68	O
%	O
±	O
0.03	O
%	O
)	O
and	O
Asian	O
(	O
-	O
0.80	O
%	O
±	O
0.03	O
%	O
)	O
patients	O
(	O
P	O
value	O
for	O
interaction	O
=	O
.56	O
)	O
;	O
analysis	O
by	O
race	O
and	O
ethnicity	O
showed	O
better	O
efficacy	O
(	O
P	O
<	O
.02	O
)	O
in	O
Japanese	O
patients	O
.	O

Placebo	O
-	O
corrected	O
HbA1c	O
reduction	O
was	O
similar	O
between	O
Caucasian	B:C0043157
(	O
-	O
0.68	O
%	O
±	O
0.03	O
%	O
)	O
and	O
Asian	O
(	O
-	O
0.80	O
%	O
±	O
0.03	O
%	O
)	O
patients	O
(	O
P	O
value	O
for	O
interaction	O
=	O
.56	O
)	O
;	O
analysis	O
by	O
race	O
and	O
ethnicity	O
showed	O
better	O
efficacy	O
(	O
P	O
<	O
.02	O
)	O
in	O
Japanese	O
patients	O
.	O

Placebo	O
-	O
corrected	O
HbA1c	O
reduction	O
was	O
similar	O
between	O
Caucasian	O
(	O
-	O
0.68	O
%	O
±	O
0.03	O
%	O
)	O
and	O
Asian	B:C0078988
(	O
-	O
0.80	O
%	O
±	O
0.03	O
%	O
)	O
patients	O
(	O
P	O
value	O
for	O
interaction	O
=	O
.56	O
)	O
;	O
analysis	O
by	O
race	O
and	O
ethnicity	O
showed	O
better	O
efficacy	O
(	O
P	O
<	O
.02	O
)	O
in	O
Japanese	O
patients	O
.	O

Placebo	O
-	O
corrected	O
HbA1c	O
reduction	O
was	O
similar	O
between	O
Caucasian	O
(	O
-	O
0.68	O
%	O
±	O
0.03	O
%	O
)	O
and	O
Asian	O
(	O
-	O
0.80	O
%	O
±	O
0.03	O
%	O
)	O
patients	O
(	O
P	O
value	O
for	O
interaction	O
=	O
.56	O
)	O
;	O
analysis	O
by	O
race	B:C0034510
and	O
ethnicity	O
showed	O
better	O
efficacy	O
(	O
P	O
<	O
.02	O
)	O
in	O
Japanese	O
patients	O
.	O

Placebo	O
-	O
corrected	O
HbA1c	O
reduction	O
was	O
similar	O
between	O
Caucasian	O
(	O
-	O
0.68	O
%	O
±	O
0.03	O
%	O
)	O
and	O
Asian	O
(	O
-	O
0.80	O
%	O
±	O
0.03	O
%	O
)	O
patients	O
(	O
P	O
value	O
for	O
interaction	O
=	O
.56	O
)	O
;	O
analysis	O
by	O
race	O
and	O
ethnicity	B:C0015031
showed	O
better	O
efficacy	O
(	O
P	O
<	O
.02	O
)	O
in	O
Japanese	O
patients	O
.	O

Placebo	O
-	O
corrected	O
HbA1c	O
reduction	O
was	O
similar	O
between	O
Caucasian	O
(	O
-	O
0.68	O
%	O
±	O
0.03	O
%	O
)	O
and	O
Asian	O
(	O
-	O
0.80	O
%	O
±	O
0.03	O
%	O
)	O
patients	O
(	O
P	O
value	O
for	O
interaction	O
=	O
.56	O
)	O
;	O
analysis	O
by	O
race	O
and	O
ethnicity	O
showed	O
better	O
efficacy	O
(	O
P	O
<	O
.02	O
)	O
in	O
Japanese	B:C1556094
patients	O
.	O

Japanese	B:C1556094
patients	O
were	O
drug	O
-	O
naïve	O
and	O
treated	O
with	I:C0332293
a	O
single	O
oral	O
anti-diabetes	O
drug	I:C1254351
only	O
;	O
they	O
showed	O
no	O
response	O
to	O
placebo	O
.	O

Japanese	O
patients	O
were	O
drug	O
-	O
naïve	O
and	O
treated	B:C0332293
with	I:C0332293
a	O
single	O
oral	O
anti-diabetes	O
drug	I:C1254351
only	O
;	O
they	O
showed	O
no	O
response	O
to	O
placebo	O
.	O

Japanese	O
patients	O
were	O
drug	O
-	O
naïve	O
and	O
treated	O
with	I:C0332293
a	O
single	O
oral	B:C0226896
anti-diabetes	O
drug	I:C1254351
only	O
;	O
they	O
showed	O
no	O
response	O
to	O
placebo	O
.	O

Japanese	O
patients	O
were	O
drug	O
-	O
naïve	O
and	O
treated	O
with	I:C0332293
a	O
single	O
oral	O
anti-diabetes	B:C1254351
drug	I:C1254351
only	O
;	O
they	O
showed	O
no	O
response	O
to	O
placebo	O
.	O

Japanese	O
patients	O
were	O
drug	O
-	O
naïve	O
and	O
treated	O
with	I:C0332293
a	O
single	O
oral	O
anti-diabetes	O
drug	I:C1254351
only	O
;	O
they	O
showed	O
no	O
response	O
to	O
placebo	B:C1696465
.	O

Weight	O
neutrality	O
of	O
vildagliptin	B:C1570906
was	O
demonstrated	O
in	O
all	O
groups	O
(	O
0.47	O
±	O
0.11	O
kg	O
to	O
-	O
0.29	O
±	O
0.08	O
kg	O
)	O
.	O

Weight	O
neutrality	O
of	O
vildagliptin	O
was	O
demonstrated	O
in	O
all	O
groups	B:C1257890
(	O
0.47	O
±	O
0.11	O
kg	O
to	O
-	O
0.29	O
±	O
0.08	O
kg	O
)	O
.	O

Hypoglycaemic	B:C0342312
events	I:C0342312
(	O
≥1	O
)	O
were	O
infrequent	O
in	O
all	O
ethnic	O
subgroups	I:C0015031
.	O

Hypoglycaemic	O
events	I:C0342312
(	O
≥1	O
)	O
were	O
infrequent	O
in	O
all	O
ethnic	B:C0015031
subgroups	I:C0015031
.	O

The	O
glycaemic	B:C0005802
efficacy	O
of	O
vildagliptin	O
was	O
similar	O
in	O
Caucasian	O
and	O
Asian	O
patients	O
.	O

The	O
glycaemic	O
efficacy	O
of	O
vildagliptin	B:C1570906
was	O
similar	O
in	O
Caucasian	O
and	O
Asian	O
patients	O
.	O

The	O
glycaemic	O
efficacy	O
of	O
vildagliptin	O
was	O
similar	O
in	O
Caucasian	B:C0043157
and	O
Asian	O
patients	O
.	O

The	O
glycaemic	O
efficacy	O
of	O
vildagliptin	O
was	O
similar	O
in	O
Caucasian	O
and	O
Asian	B:C0078988
patients	O
.	O

The	O
slightly	O
better	O
efficacy	O
observed	O
in	O
Japanese	B:C1556094
patients	O
was	O
driven	O
by	O
the	O
absence	O
of	O
placebo	O
effect	O
and	O
might	O
be	O
explained	O
by	O
their	O
earlier	O
stage	O
of	O
diabetes	O
compared	O
to	O
other	O
subgroups	O
.	O

The	O
slightly	O
better	O
efficacy	O
observed	O
in	O
Japanese	O
patients	O
was	O
driven	O
by	O
the	O
absence	O
of	O
placebo	O
effect	O
and	O
might	O
be	O
explained	O
by	O
their	O
earlier	O
stage	O
of	O
diabetes	B:C0011847
compared	O
to	O
other	O
subgroups	O
.	O

The	O
slightly	O
better	O
efficacy	O
observed	O
in	O
Japanese	O
patients	O
was	O
driven	O
by	O
the	O
absence	O
of	O
placebo	O
effect	O
and	O
might	O
be	O
explained	O
by	O
their	O
earlier	O
stage	O
of	O
diabetes	O
compared	O
to	O
other	O
subgroups	B:C1257890
.	O

